NUVL News and Press, Nuvalent Inc. From 05/11/23

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results PR Newswire Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-...

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days PR Newswire CAMBRIDGE, Mass. , April 19, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therap...

Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 PR Newswire CAMBRIDGE, Mass. , April 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creat...

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) PR Newswire CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on c...

2023-03-16 08:38:15 ET Nuvalent press release ( NASDAQ: NUVL ): Q4 GAAP EPS of -$0.49. Cash, cash equivalents and marketable securities were $472.2 million For further details see: Nuvalent GAAP EPS of -$0.49

Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire Significant progress made across pipeline of novel kinase inhibitors with parallel-lead programs in ongoing Phase 1 clinical trials and a third progra...

Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference PR Newswire CAMBRIDGE, Mass. , March 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies ...

Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc. , (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi...

Summary Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading ...

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case stud...